Medical insurance policy for valganciclovir after its launch in the country

Valganciclovir is an important antiviral drug for the treatment of diseases related to cytomegalovirus (CMV) infection. Its domestic launch provides a key treatment option for organ transplant patients and people with low immune function. The original drug has been approved in China, but so far it has not been included in the medical insurance list, which means that patients need to bear all the cost of the drug when using it. Taking the specification of 0.45g*60 tablets as an example, the price per box may exceed 10,000 yuan, which limits the accessibility to patients to a certain extent, especially the continuous medication required for long-term prevention and maintenance treatment.

Although it has not yet been included in medical insurance, the clinical value of valganciclovir cannot be ignored. As an oral antiviral small molecule drug, it has advantages in efficacy, pharmacokinetics and safety. Compared with intravenous medication regimens, it is more convenient for patients to manage at home after discharge. This also leads hospitals and patients to make a trade-off between economy and treatment needs. Some patients may choose overseas or generic versions as alternatives to reduce treatment costs.

With the increase in the number of domestic organ transplant patients and the emphasis on CMV prevention and treatment, medical insurance policies are expected to gradually cover valganciclovir in the future, making its price burden more reasonable and improving drug accessibility. At the same time, hospital pharmacies, clinical pharmacists and doctors are also actively promoting standardized management and optimizing drug use plans by rationally assessing the risks of high-risk patients to ensure that drugs can not only exert their efficacy but also take into account economics.

To sum up, the domestic launch of valganciclovir provides an important treatment for CMV high-risk groups, but its medical insurance coverage still needs to be further promoted, and patients need to make personalized decisions based on their economic situation, clinical needs and physician guidance when using it.

Reference materials:https://go.drugbank.com/drugs/DB01610